Tablets: Azoximer bromide 12 mg
Inactive ingredients: mannitol 3.6 mg, povidone К17 2.4 mg, lactose monohydrate 185 mg, potato starch 45 mg, stearic acid 2 mg.
Vials: 1 bottle contains:
Active ingredient: Azoximer bromide 3 mg or 6 mg
Inactive ingredients: mannitol 0.9 mg, povidone К17 0.6 mg (for 3 mg dosage); mannitol 1.8 mg, povidone К17 1.2 mg (for 6 mg dosage).
Influenza and URI treatment course lasts 7 days.
Tablets: Apply orally and sublingually 20-30 minutes before meal twice a day. Dosage for adults and children from 10 years of age is 1 tablet, dosage for children aged 3 to 10 is 1/2 tablet (6 mg).
If necessary, treatment courses can be repeated after 3-4 months. Effectiveness is not reduced on repeat prescription.
Vials: For intramuscular injection dilute 3 mg of Polyoxidonium in 1 ml (6 mg in 2 ml) of water for injections or 0.9% sodium chloride solution. After the dilution leave for 2-3 minutes and then stir without shaking.
Preparing a solution for intranasal or sublingual administration: for use in children dilute 3 mg dosage in 1.0 ml (20 drops), 6 mg dosage in 2.0 ml (40 drops) (1 drop (0.05 ml) of prepared solution contains 0.15 mg of the drug); for use in adults dilute 6 mg dosage in 1.0 ml (20 drops) of 0.9% sodium chloride solution or boiled water.
Parenterally (intramuscular or intravenous): dosage for adults is 6-12 mg once a day daily, every other day or 1-2 times a week depending on the diagnosis and disease severity.
Daily doses for children (intranasal or sublingual administration): 1 drop per 1 kg, but no more than 40 drops (6 mg of the active ingredient).
A prepared solution for intranasal or sublingual administration can be stored at room temperature in manufacturer’s package for up to 48 hours.
Side effects are not registered.
Cases of overdose are not registered.
Azoximer bromide does not inhibit CYP1A2, CYP2C9, CYP2C19 and CYP2D6 isoenzymes, so Polyoxidonium can be administered with antibiotics, antivirals, antifungal and antihistamine preparations, glucocorticoids, and cytostatics.
Keep out of the reach of children. Store at 2-25°С (35,6 - 77) °F.
Polyoxidonium is a medicine intended for stimulating the immune system. Its active ingredient is azoximer bromide (copolymer N-oxide 1,4-ethylene piperazine and (N- carboxymethyl)-1,4-ethylene piperazinium bromide).
Polyoxidonium was developed by a group of scientists in the National Research Centre – Institute of Immunology of the Federal Biomedical Agency of Russia. Though the active ingredient was patented in 1997, the drug has been in clinical use since 1996. It has been proven to be effective and safe to use and gained popularity both among doctors and patients. Polyoxidonium is one of Top 200 medicines in Russia and it is included in the Russian list of vital and essential drugs.
Polyoxidonium has a complex effect as it is an immunomodulator with detoxifying and antioxidant properties. It restores immunity and detoxifies, thus improving patients’ general condition as well as reducing the risk of developing complications. Unlike many immunomodulators, Polyoxidonium can be used in acute conditions such as influenza, cold and inflammatory infections of any origin. It can be well combined with standard therapy as it enhances its effect, improves body resistance and detoxifies.
Polyoxidonium is a “smart” immunomodulator – it increases the low and lowers the high indicators of the immune system, not affecting the normal ones.
One of the facts that prove its effectiveness is that Polyoxidonium is included as an adjuvant in trivalent and quadrivalent influenza vaccines which are exported by Petrovax (the manufacturer) into the Republic of Belarus, Kazakhstan, Kyrgyzstan, Iran, etc.
Polyoxidonium in intranasal form can be used in children from six months of age, which proves its safety.
The manufacturer's official website – polyoxidonium.ru
The drug can be applied orally, intranasally or intramuscularly.
The drug has two pharmaceutical forms: a pack of 10 tablets containing dosage of 12 mg and a pack of 5 bottles with lyophilisate for solution for injection and topical administration. One pack is sufficient for a 5-day course aimed at treating influenza and URI.
- Bratchikov et al (2008) Upgrading of clinicoimmunological effectiveness of combined treatment in patients with chronic prostatitis https://www.ncbi.nlm.nih.gov/m/pubmed/18572770/?i=3&from=Azoximer
- Porfiriadis et al (2010) Increase of the treatment efficacy of the slow developing phlegmonas of maxillofacial region with the help immunomodulator Polyoxidonium https://www.ncbi.nlm.nih.gov/pubmed/21186650
- No authors listed (2010) POLYOXIDONIUM IN COMPLEX PREVENTIVE TREATMENT FOR TUBERCULOSIS IN CHILDREN AND ADOLESCENTS https://www.ncbi.nlm.nih.gov/pubmed/27529931/
- V Bulgakova (2014) Immunomodulators for the prevention and treatment of acute respiratory infections: efficacy of azoximer bromide https://www.ncbi.nlm.nih.gov/pubmed/25804048
- Pružinec et al (2017) The safety profile of Polyoxidonium in daily practice: results from postauthorization safety study in Slovakia https://www.futuremedicine.com/doi/abs/10.2217/imt-2017-0116?url_ver=Z39.88-2003&rfr_dat=cr_pub%3Dpubmed&rfr_id=ori%3Arid%3Acrossref.org&journalCode=imt